CDEK
← All drugs Report issue

ketanserin

Small moleculeexperimental

Ketanserin, sold under the brand name Sufrexal, is an antihypertensive agent which is used to treat arterial hypertension and vasospastic disorders. It is also used in scientific research as an antiserotonergic agent in the study of the serotonin system; specifically, the 5-HT2 receptor family. The drug is taken by mouth. — Wikipedia

Clinical trial activity

22 trials · 13 clinical orgs · 0 marketing orgs

Phase 1
13
Phase 2
7
Phase 3
2
Phase 4
1

Earliest trial started Apr 1, 2008 (NCT00557219)

Timeline

2000s

  1. Jan 1, 2008

    Earliest Phase 3 Sponsor(trial)

2010s

  1. Jan 1, 2014

    Earliest Phase 1 Sponsor(trial)

  2. Jan 1, 2019

    Earliest Phase 2 Sponsor(trial)

Indications

Approved for

Studied for

Mechanism of action

Chemistry & pharmacology

Loading structure…

SMILES

O=C(c1ccc(F)cc1)C1CCN(CCn2c(=O)[nH]c3ccccc3c2=O)CC1
Mol. weight
395.43 g/mol
Lipinski Ro5
Pass
Rule of 3
No
Chirality
Achiral Molecule
Inorganic
No
Polymer
No

Oral

No

Parenteral

No

Topical

No

Sources

Also known as

  • ketanserin
  • ketanserin
  • ketanserin
  • ketanserin
  • ketanserin
  • ketanserin
  • ketanserin tartrate
  • ketanserin tartrate hydrate
  • ketensin
  • r 41468
  • r 41 468
  • r 41 468
  • r 41 468
  • r 41 468
  • r 41 468
  • r-41468
  • r-41468
  • suffrexal
  • sufrexal
  • sufrexal

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT07309471N/AJan 31, 2026University of Basel
NCT07061886Early Phase 1 (Phase 1)Jun 26, 2025National Institute on Drug Abuse (NIDA), University of Chicago
NCT07017478Early Phase 1 (Phase 1)Jun 9, 2025National Institute on Drug Abuse (NIDA), University of Chicago
NCT06796361Phase 1Apr 21, 2025University of Basel
NCT06899334Phase 1Apr 1, 2025University of Basel
NCT05964647Phase 1Dec 1, 2023University of Basel
NCT05953038Early Phase 1 (Phase 1)Nov 8, 2023University of Copenhagen
NCT05976698N/ASep 30, 2023University of Basel
NCT05883540Phase 2Sep 30, 2023University of Basel, University of Zurich
NCT05474989Phase 2Jan 1, 2023University of Basel, University of Bern, University of Geneva
NCT05670184Phase 1/Phase 2 (Phase 2)Jan 1, 2023Maastricht University
NCT04849013Phase 1Aug 11, 2021University of Basel
NCT04558294Phase 1Oct 16, 2020University of Basel
NCT04227756Phase 1Apr 1, 2020University of Basel
NCT03866252Phase 2Jun 30, 2019University of Basel
NCT03646318Phase 4Sep 1, 2018Medical Center Leeuwarden, Onze Lieve Vrouw Hospital
NCT03321136Early Phase 1 (Phase 1)Nov 28, 2017University of Basel
NCT03289949Phase 1Mar 3, 2017University of Copenhagen
NCT02451072N/AMar 1, 2015University of Zurich
NCT02632877Phase 1/Phase 2 (Phase 2)Jan 1, 2014Cell Pharma, University of Guadalajara
Showing 20 of 22 trials
Page 1 / 2

Organizations

Research & Development (13)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
University of BaselAcademic/Hospital121232017
Medical Center LeeuwardenAcademic/Hospital2122011
National Institute on Drug Abuse (NIDA)Government2012025
University of ChicagoAcademic/Hospital2212025
University of CopenhagenAcademic/Hospital2212017
University of ZurichAcademic/Hospital2122015
Cell PharmaFor profit1012014
Maastricht UniversityAcademic/Hospital1112023
Medical University of GdanskAcademic/Hospital1112008
Onze Lieve Vrouw HospitalAcademic/Hospital1112018
University of BernAcademic/Hospital1012023
University of GenevaAcademic/Hospital1012023
University of GuadalajaraAcademic/Hospital1112014
13 organizations
Page 1 / 1